Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Pulm Med. 2011 Nov;17(6):461-6. doi: 10.1097/MCP.0b013e32834b7f51.

Liver disease in cystic fibrosis.

Author information

  • 1Dublin Academic Medical Centre, UCD School of Medicine and Medical Science, Dublin, Ireland. marion.rowland@ucd.ie

Abstract

PURPOSE OF REVIEW:

This review looks at what is currently known about liver disease in cystic fibrosis (CF) in light of the literature over the past year, and what the ongoing challenges are from a clinical and research perspective for the optimal management of cystic fibrosis liver disease (CFLD).

RECENT FINDINGS:

Patients with CF who develop clinically significant liver disease have a worse overall phenotype, and whereas there is no definite evidence that they have a shorter life expectancy, longer follow-up is required to determine if liver disease is a risk factor for mortality in CF.The development of the ferret and pig animal models of CF with multiorgan involvement is an important breakthrough which will enhance our understanding of the pathogenesis of CFLD, and with which it is hoped novel therapeutic targets for the treatment of CFLD will be identified.

SUMMARY:

Whereas there is still no effective treatment for liver disease in CF, recent developments of animal models of CFLD will enhance our capacity to develop new therapeutic targets and reduce the impact of liver disease on mortality in CF.

© 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins

PMID:
21881510
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk